Aquestive Q1 net loss $22.9M; cuts FY revenue guidance on Libervant setback

Aquestive Therapeutics, Inc.

2025-Q1 EPS reported -$0.24 revenue$8,720,000

Total revenue $8.7M, down 28% YoY from $12.1M; net loss $0.24/share vs $0.17 loss last year.
NDA for Anaphylm submitted; plans Q1 2026 launch if FDA approved; will not appeal Libervant court decision.
Libervant reclassified to tentative approval; sales/marketing paused; FY revenue guidance cut to $44-50M.
Non-GAAP adjusted EBITDA loss $17.6M vs $7.2M prior year; cash $68.7M.
De-emphasizing AQST-108 (alopecia) until after Anaphylm launch to focus resources.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.